Detalles de la búsqueda
1.
Donor-derived CMV-specific T cells reduce the requirement for CMV-directed pharmacotherapy after allogeneic stem cell transplantation.
Blood
; 121(18): 3745-58, 2013 May 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-23435462
2.
Low-cost generation of Good Manufacturing Practice-grade CD19-specific chimeric antigen receptor-expressing T cells using piggyBac gene transfer and patient-derived materials.
Cytotherapy
; 17(9): 1251-67, 2015 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-26212611
3.
A phase III randomized trial of high-dose CEOP + filgrastim versus standard-dose CEOP in patients with non-Hodgkin lymphoma: 10-year follow-up data: Australasian Leukaemia and Lymphoma Group (ALLG) NHL07 trial.
Am J Hematol
; 89(5): 536-41, 2014 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-24481640
4.
Prophylactic antigen-specific T-cells targeting seven viral and fungal pathogens after allogeneic haemopoietic stem cell transplant.
Clin Transl Immunology
; 10(3): e1249, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-33747509
5.
Long-term control of recurrent or refractory viral infections after allogeneic HSCT with third-party virus-specific T cells.
Blood Adv
; 1(24): 2193-2205, 2017 Nov 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-29296867
Resultados
1 -
5
de 5
1
Próxima >
>>